Tag: Competition

Posted on

Glaxo in for competition after Hikma’s generic asthma drug passes major milestone – Telegraph.co.uk


Telegraph.co.uk

Glaxo in for competition after Hikma's generic asthma drug passes major milestone
Telegraph.co.uk
Cheap versions of one of GlaxoSmithKline's top-selling asthma drugs could be available to patients as early as next year. Jordanian pharmaceuticals company Hikma moved one step closer to getting a generic version of Glaxo's Advair Diskus inhaler onto …
Cipla's rival Hikma gets asthma drug nod in the USMoneycontrol.com
Vectura and Hikma's generic of Advair Diskus accepted for filing by US FDAThe Pharma Letter (registration)
Vectura Group PLC and Hikma shares given FDA boostProactive Investors UK

all 8 news articles »

View full post on asthma – Google News

Posted on

Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma … – Washington Post


Proactive Investors USA & Canada

Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma …
Washington Post
Drugmaker Merck & Co. said Friday that third-quarter profit rose 2 percent as reduced spending on overhead offset lower sales due to new generic competition for its top-selling drug, Singulair. The maker of diabetes pill Januvia beat Wall Street's …
Merck tops view, newer drugs cushion asthma drug blowGlobe and Mail
Merck Q3 earnings edge up despite decline in salesProactive Investors USA & Canada
Merck's Profit Rises 2.2%Wall Street Journal
Chicago Tribune –Fox Business
all 221 news articles »

View full post on asthma – Google News

Posted on

Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma … – Newser


Globe and Mail

Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma …
Newser
The maker of diabetes pill Januvia beat Wall Street's profit expectations. The company also narrowed its 2012 profit forecast, to a range of $2.08 to $2.24 per share, from its July forecast of $2.04 to $2.30. Merck, based in Whitehouse Station, N.J …
Merck tops view, newer drugs cushion asthma drug blowGlobe and Mail
Merck posts mixed results for third quarterChicago Tribune
MERCK & CO., INC. : Merck 3rd-Quarter Profit Up 2.2%; Narrows Year View4-traders
Fox Business –The Markets Are Open (blog)
all 161 news articles »

View full post on asthma – Google News

Posted on

Growing Prevalence of Asthma is Fueling Vigorous Industry Competition for … – Sacramento Bee

Growing Prevalence of Asthma is Fueling Vigorous Industry Competition for …
Sacramento Bee
NEW YORK, Sept. 17, 2012 — /PRNewswire/ — Citeline®, an Informa business, reviewed clinical trial data presented at the European Respiratory Society (ERS) conference, held September 1-5, 2012 in Vienna, Austria, noting that classical fixed-dose …

View full post on asthma – Google News

Posted on

Growing Prevalence of Asthma is Fueling Vigorous Industry Competition for … – RedOrbit

Growing Prevalence of Asthma is Fueling Vigorous Industry Competition for …
RedOrbit
Respiratory drug leader GSK presented largely positive results from five pivotal Relvar (formerly Relovair) asthma trials. The results, submitted in July as part of the company's regulatory filing for asthma in the EU, demonstrated improved efficacy …

and more »

View full post on asthma – Google News